| pubmed-article:15610448 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15610448 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15610448 | lifeskim:mentions | umls-concept:C0346976 | lld:lifeskim |
| pubmed-article:15610448 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:15610448 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:15610448 | pubmed:dateCreated | 2004-12-21 | lld:pubmed |
| pubmed-article:15610448 | pubmed:abstractText | A previous randomized trial showed gemcitabine was superior to 5-fluorouracil in overall patient survival. However, the incremental improvement in survival was minimal. It is 2.5 years since gemcitabine has become available for the treatment of pancreatic cancer in clinical practice in Japan. The current study was conducted to examine whether treatment outcomes have changed since the introduction of gemcitabine therapy. | lld:pubmed |
| pubmed-article:15610448 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15610448 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15610448 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15610448 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15610448 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15610448 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15610448 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15610448 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:15610448 | pubmed:issn | 0815-9319 | lld:pubmed |
| pubmed-article:15610448 | pubmed:author | pubmed-author:IshiiHiroshiH | lld:pubmed |
| pubmed-article:15610448 | pubmed:author | pubmed-author:FuruseJunjiJ | lld:pubmed |
| pubmed-article:15610448 | pubmed:author | pubmed-author:YoshinoMasahi... | lld:pubmed |
| pubmed-article:15610448 | pubmed:author | pubmed-author:NagaseMichita... | lld:pubmed |
| pubmed-article:15610448 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15610448 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:15610448 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15610448 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15610448 | pubmed:pagination | 62-6 | lld:pubmed |
| pubmed-article:15610448 | pubmed:meshHeading | pubmed-meshheading:15610448... | lld:pubmed |
| pubmed-article:15610448 | pubmed:meshHeading | pubmed-meshheading:15610448... | lld:pubmed |
| pubmed-article:15610448 | pubmed:meshHeading | pubmed-meshheading:15610448... | lld:pubmed |
| pubmed-article:15610448 | pubmed:meshHeading | pubmed-meshheading:15610448... | lld:pubmed |
| pubmed-article:15610448 | pubmed:meshHeading | pubmed-meshheading:15610448... | lld:pubmed |
| pubmed-article:15610448 | pubmed:meshHeading | pubmed-meshheading:15610448... | lld:pubmed |
| pubmed-article:15610448 | pubmed:meshHeading | pubmed-meshheading:15610448... | lld:pubmed |
| pubmed-article:15610448 | pubmed:meshHeading | pubmed-meshheading:15610448... | lld:pubmed |
| pubmed-article:15610448 | pubmed:meshHeading | pubmed-meshheading:15610448... | lld:pubmed |
| pubmed-article:15610448 | pubmed:meshHeading | pubmed-meshheading:15610448... | lld:pubmed |
| pubmed-article:15610448 | pubmed:meshHeading | pubmed-meshheading:15610448... | lld:pubmed |
| pubmed-article:15610448 | pubmed:meshHeading | pubmed-meshheading:15610448... | lld:pubmed |
| pubmed-article:15610448 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15610448 | pubmed:articleTitle | Impact of gemcitabine on the treatment of metastatic pancreatic cancer. | lld:pubmed |
| pubmed-article:15610448 | pubmed:affiliation | Division of Hepatobiliary and Pancreatic Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan. hirishii@east.ncc.go.jp | lld:pubmed |
| pubmed-article:15610448 | pubmed:publicationType | Journal Article | lld:pubmed |
